Evidence map›Paper›PMID 40385472›Full record

ReviewFrontiers in pharmacology2025

1-Nitro-2-phenylethane: a promising phytoconstituent to modulate neuroinflammation and oxidative stress with repercussions on neurological and psychiatric disorders.

Lucas Villar Pedrosa Silva Pantoja, Emily Christie Maia Fonseca, Fábio José Coelho Souza-Junior, Brenda Costa da Conceição, Sarah Viana Farias, Joyce Kelly R da Silva, José Guilherme Soares Maia, Pedro Iuri Castro Silva, Jofre Jacob Silva Freitas, Rui Daniel Prediger and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lucas Villar Pedrosa Silva Pantoja *Laboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Emily Christie Maia Fonseca *Laboratório de Biotecnologia de Enzimas e Biotransformações, Universidade Federal do Pará, Belém, Para, Brazil.
Fábio José Coelho Souza-Junior *Laboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Brenda Costa da ConceiçãoLaboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Sarah Viana FariasLaboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Joyce Kelly R da SilvaLaboratório de Biotecnologia de Enzimas e Biotransformações, Universidade Federal do Pará, Belém, Para, Brazil.
José Guilherme Soares MaiaPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pará, Belém, Para, Brazil.
Pedro Iuri Castro SilvaLaboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Jofre Jacob Silva FreitasCentro de Estudos Pré-Clínicos da Amazônia, Universidade do Estado do Pará, Belém, Para, Brazil.
Rui Daniel PredigerLaboratório Experimental de Doenças Neurodegenerativas, Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil.
Daniele Luz CamposLaboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Enéas Andrade Fontes-JúniorLaboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.
Cristiane Socorro Ferraz MaiaLaboratório de Farmacologia da Inflamação e do Comportamento, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Para, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurologic and neuropsychiatric disorders are complex, with common pathophysiological mechanisms associated with inflammation, oxidative stress, and vascular damage. These shared features have stimulated interest in bioactive compounds with neuropharmacological potential. In this regard, the 1-Nitro-2-Phenylethane (1N2PE) emerges as a promissory compound to act on the multiple via of brain disturbances. However, its neuropharmacological mechanisms of action remain largely unknown. We aim to provide a comprehensive overview of the scarce literature on the effects of 1N2PE in brain disorders to highlight the importance of further research into the mechanisms of action and its potential applications in the field of neurology and psychiatry, focusing on the anti-inflammatory and antioxidant properties. The 1N2PE exhibits neuroprotective properties, including anti-inflammatory, antioxidant, and cholinergic-enhancing effects, which together may underlie its potential therapeutic benefits for various neuropsychiatric and neurological disorders, such as depression, anxiety, seizures, and cognitive impairments. This review compiles literature on 1N2PE potential central nervous system activities, highlighting its therapeutic potential in treating behavioral and neurological disorders. Despite promising findings, further research is essential to fully understand 1N2PE as a novel therapeutic agent.

Indexed as

1-Nitro-2-phenylethaneAniba canelillaNeuroinflammationoxidative stresspsychiatric illness

Identifiers

PMID40385472
PMCPMC12082040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.